Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (581-590 of 745) with videos related to

Pageof 75
Sort By:
Cancer Medicine|October 18, 2013
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastasesHeike Niessner, Andrea Forschner, Bernhard Klumpp, et al.
Med (New York, N.Y.)|April 9, 2024
Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanomaRamona Schlenker, Petra C Schwalie, Steffen Dettling, et al.
Nature Medicine|October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-iReinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
Cancer Research|February 5, 2008
Modeling genomic diversity and tumor dependency in malignant melanomaWilliam M Lin, Alissa C Baker, Rameen Beroukhim, et al.
The New England Journal of Medicine|September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated MelanomaGeorgina V Long, Axel Hauschild, Mario Santinami, et al.
Radiation Oncology (London, England)|December 15, 2020
Correction to: Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : Melanoma brain metastases prognostic scoreJana Schaule, Stephanie G C Kroeze, Oliver Blanck, et al.
The Lancet. Oncology|March 26, 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialReinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2024
Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE studyMichael Weller, Emilie Le Rhun, Lydia Tsamtsouri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2017
Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of KlothoReeti Behera, Amanpreet Kaur, Marie R Webster, et al.
The Lancet. Oncology|September 17, 2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
Pageof 75

Showing results (581-590 of 745) with videos related to

Sort By:
Pageof 75
Cancer Medicine|October 18, 2013
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastasesHeike Niessner, Andrea Forschner, Bernhard Klumpp, et al.
Med (New York, N.Y.)|April 9, 2024
Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanomaRamona Schlenker, Petra C Schwalie, Steffen Dettling, et al.
Nature Medicine|October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-iReinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
Cancer Research|February 5, 2008
Modeling genomic diversity and tumor dependency in malignant melanomaWilliam M Lin, Alissa C Baker, Rameen Beroukhim, et al.
The New England Journal of Medicine|September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated MelanomaGeorgina V Long, Axel Hauschild, Mario Santinami, et al.
Radiation Oncology (London, England)|December 15, 2020
Correction to: Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : Melanoma brain metastases prognostic scoreJana Schaule, Stephanie G C Kroeze, Oliver Blanck, et al.
The Lancet. Oncology|March 26, 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialReinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2024
Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE studyMichael Weller, Emilie Le Rhun, Lydia Tsamtsouri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2017
Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of KlothoReeti Behera, Amanpreet Kaur, Marie R Webster, et al.
The Lancet. Oncology|September 17, 2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
Pageof 75